HRP20060286T3 - Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof - Google Patents

Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof

Info

Publication number
HRP20060286T3
HRP20060286T3 HR20060286T HRP20060286T HRP20060286T3 HR P20060286 T3 HRP20060286 T3 HR P20060286T3 HR 20060286 T HR20060286 T HR 20060286T HR P20060286 T HRP20060286 T HR P20060286T HR P20060286 T3 HRP20060286 T3 HR P20060286T3
Authority
HR
Croatia
Prior art keywords
ring
thioxy
haloalkylsulfinyl
haloalkylsulfonyl
haloalkylthio
Prior art date
Application number
HR20060286T
Other languages
English (en)
Croatian (hr)
Inventor
Semple Graeme
Schrader Thomas
J. Skinner Philip
L. Colletti Steven
E. Imbriglio Jason
Liang Rui
Raghavan Subharekha
Schmidt Darby
R. Tata James
Gharbaoui Tawfik
Jung Jae-Kyu
Original Assignee
Arena Pharmaceuticals Inc
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc, Merck & Co. Inc. filed Critical Arena Pharmaceuticals Inc
Publication of HRP20060286T3 publication Critical patent/HRP20060286T3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20060286T 2003-10-31 2004-10-29 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof HRP20060286T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51623803P 2003-10-31 2003-10-31
PCT/US2004/035927 WO2005044816A1 (en) 2003-10-31 2004-10-29 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof

Publications (1)

Publication Number Publication Date
HRP20060286T3 true HRP20060286T3 (en) 2007-03-31

Family

ID=34572875

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20060286T HRP20060286T3 (en) 2003-10-31 2004-10-29 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof

Country Status (37)

Country Link
US (2) US8637555B2 (de)
EP (2) EP1599469B1 (de)
JP (2) JP4533898B2 (de)
KR (1) KR100850591B1 (de)
CN (1) CN1867562B (de)
AR (1) AR046611A1 (de)
AT (1) ATE328880T1 (de)
AU (1) AU2004287861B2 (de)
BR (1) BRPI0415631A (de)
CA (1) CA2539985C (de)
CO (1) CO5690551A2 (de)
CR (1) CR8270A (de)
CY (1) CY1105479T1 (de)
DE (1) DE602004001134T2 (de)
DK (1) DK1599469T3 (de)
EA (1) EA011484B1 (de)
EC (1) ECSP066529A (de)
ES (1) ES2267077T3 (de)
GE (1) GEP20094801B (de)
HR (1) HRP20060286T3 (de)
IL (1) IL174042A0 (de)
IS (1) IS2372B (de)
MA (1) MA28171A1 (de)
MX (1) MXPA06004556A (de)
MY (1) MY140410A (de)
NO (1) NO20062509L (de)
NZ (1) NZ546285A (de)
PE (1) PE20050483A1 (de)
PL (1) PL1599469T3 (de)
PT (1) PT1599469E (de)
RS (1) RS20060290A (de)
SI (1) SI1599469T1 (de)
TN (1) TNSN06150A1 (de)
TW (1) TWI258478B (de)
UA (1) UA86783C2 (de)
WO (1) WO2005044816A1 (de)
ZA (2) ZA200603419B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
ES2331521T3 (es) 2003-11-21 2010-01-07 Arena Pharmaceuticals, Inc. Derivados de acido 4-oxo-4,5-dihidro-furan-2-carboxilico y procedimientos de tratamiento de trastornos metabolicos relacionados del mismo.
US20070244107A1 (en) * 2004-08-25 2007-10-18 Waters M Gerard Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
EP1811996A1 (de) * 2004-11-05 2007-08-01 Arena Pharmaceuticals, Inc. Zusammensetzungen zur behandlung von hitzewallungen und lipidabhängigen störungen mit niacin-rezeptor-teilagonisten
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
EP1877402A1 (de) 2005-04-28 2008-01-16 Merck Sharp & Dohme Limited Verfahren zur herstellung von tetrazolyltetrahydrocyclopentapyrazolen
CA2611552A1 (en) 2005-06-28 2007-01-04 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
DE102006021733A1 (de) * 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CA2901636A1 (en) 2013-02-21 2014-08-28 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
JP6453216B2 (ja) * 2013-07-23 2019-01-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ縮合環化合物
CN103755637A (zh) * 2013-12-26 2014-04-30 平湖优康药物研发有限公司 一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺
US12086719B2 (en) * 2019-10-11 2024-09-10 Royal Bank Of Canada System and method of machine learning using embedding networks

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02178263A (ja) * 1988-12-27 1990-07-11 Kaken Pharmaceut Co Ltd アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤
US5134155A (en) * 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
CA2275796A1 (en) 1996-12-23 1998-07-02 Donald Joseph Phillip Pinto Nitrogen containing heteroaromatics as factor xa inhibitors
DE69941777D1 (de) 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
KR20030010589A (ko) 2000-03-09 2003-02-05 오노 야꾸힝 고교 가부시키가이샤 인돌 유도체, 그 제조 방법 및 용도
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
CA2413702A1 (en) 2000-06-28 2002-01-03 Teva Pharmaceuticals Industries Ltd. Carvedilol
CA2413134C (en) 2000-06-30 2010-05-11 Glaxo Group Limited Quinazoline ditosylate salt compounds
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
DE60215000T2 (de) 2001-05-23 2007-08-09 Merck Frosst Canada & Co, Kirkland Dihydropyrroloil[1,2-a]indol- und Tetrahydropyridol[1,2-a]indol-Derivate als Prostaglandin-D2-Rezeptor-Antagonisten
BR0210102A (pt) 2001-06-01 2004-06-08 Hoffmann La Roche Derivados de pirimidina, triazina e pirazina como receptores de glutamato
AU2002316421B2 (en) 2001-06-26 2008-05-15 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-ALPHA expression
JP3968076B2 (ja) 2001-06-27 2007-08-29 アールエス テック コーポレイション 新しいキラルサレン化合物、キラルサレン触媒及びこれを利用したラセミックエポキシ化合物からキラル化合物を製造する方法
EP1424335A4 (de) 2001-09-07 2005-11-16 Ono Pharmaceutical Co Indolderivate
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
CN100378083C (zh) 2002-03-19 2008-04-02 小野药品工业株式会社 羧酸化合物和含有所述化合物作为活性成分的药物制剂
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
US20060167270A1 (en) 2002-10-10 2006-07-27 Arena Pharmaceuticals Inc. 5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
DE10261131A1 (de) 2002-12-20 2004-07-01 Grünenthal GmbH Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
CA2528834A1 (en) 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
GB0319126D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
CA2556073C (en) 2004-02-14 2012-01-10 Smithkline Beecham Corporation 8-chloro-1,3-disubstituted xanthine derivatives as hm74a receptor modulators
US20070244107A1 (en) 2004-08-25 2007-10-18 Waters M Gerard Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
EP1811996A1 (de) 2004-11-05 2007-08-01 Arena Pharmaceuticals, Inc. Zusammensetzungen zur behandlung von hitzewallungen und lipidabhängigen störungen mit niacin-rezeptor-teilagonisten
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
EP1877402A1 (de) 2005-04-28 2008-01-16 Merck Sharp & Dohme Limited Verfahren zur herstellung von tetrazolyltetrahydrocyclopentapyrazolen

Also Published As

Publication number Publication date
US8637555B2 (en) 2014-01-28
MY140410A (en) 2009-12-31
CA2539985A1 (en) 2005-05-19
PL1599469T3 (pl) 2006-10-31
PT1599469E (pt) 2006-10-31
AR046611A1 (es) 2005-12-14
ECSP066529A (es) 2006-10-10
BRPI0415631A (pt) 2006-12-12
ES2267077T3 (es) 2007-03-01
RS20060290A (sr) 2008-11-28
MA28171A1 (fr) 2006-09-01
KR100850591B1 (ko) 2008-08-05
CY1105479T1 (el) 2010-07-28
CN1867562B (zh) 2011-07-13
NZ546285A (en) 2010-04-30
CO5690551A2 (es) 2006-10-31
EP1683794A1 (de) 2006-07-26
GEP20094801B (en) 2009-10-26
ATE328880T1 (de) 2006-06-15
CA2539985C (en) 2010-02-16
PE20050483A1 (es) 2005-08-25
NO20062509L (no) 2006-06-26
IL174042A0 (en) 2006-08-01
DE602004001134D1 (de) 2006-07-20
TW200530221A (en) 2005-09-16
US20060217562A1 (en) 2006-09-28
EA200600879A1 (ru) 2006-10-27
AU2004287861A1 (en) 2005-05-19
SI1599469T1 (sl) 2006-10-31
WO2005044816A1 (en) 2005-05-19
AU2004287861B2 (en) 2008-08-14
IS2372B (is) 2008-06-15
JP4533898B2 (ja) 2010-09-01
EP1599469A1 (de) 2005-11-30
ZA200603419B (en) 2006-10-25
DK1599469T3 (da) 2006-10-09
IS8481A (is) 2006-05-24
MXPA06004556A (es) 2006-07-06
US20070072924A1 (en) 2007-03-29
KR20060073974A (ko) 2006-06-29
TNSN06150A1 (en) 2007-11-15
JP2007509181A (ja) 2007-04-12
CR8270A (es) 2006-10-06
TWI258478B (en) 2006-07-21
ZA200606203B (en) 2007-04-25
EA011484B1 (ru) 2009-04-28
JP2010163448A (ja) 2010-07-29
CN1867562A (zh) 2006-11-22
DE602004001134T2 (de) 2007-04-19
UA86783C2 (ru) 2009-05-25
EP1599469B1 (de) 2006-06-07
HK1076468A1 (en) 2006-01-20

Similar Documents

Publication Publication Date Title
SE0202463D0 (sv) Novel compounds
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
TW200745029A (en) Sulfonamide derivatives exhibiting PGD2 receptor antagonism
BR9809451A (pt) Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38.
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
EA200500377A1 (ru) Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)
PL378555A1 (pl) Sulfonoamido-podstawione pochodne ksantyny do stosowania jako inhibitory PEPCK
ES2189968T3 (es) Amidinofenil-pirrolidinas,-pirrolinas,e -isoxazolidinas y derivadOS DE LOS MISMOS.
CO5690551A2 (es) Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo
WO2004100865A3 (en) New benzimidazole derivatives
SE0402762D0 (sv) Indazole sulphonamide derivatives
ATE316962T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
DE60023008D1 (de) Mittel zur verhinderung der chronischen abstossreaktion infolge einer organtransplantation
GB0308201D0 (en) Novel compounds
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
EA200700848A1 (ru) Ингибиторы pi3-гамма-киназы для лечения анемии
ATE505462T1 (de) Neue biologischaktive molekü le
MXPA05009282A (es) Derivados de anilina sustituidos.
DK1165544T3 (da) Substituerede 1,4-dihydroindeno[1,2-c]pyrazoler som inhibitorer af tyrosinkinase
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors